Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
Supplemental Material
ajp_167_02_181_01.pdf (267 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×ajp_167_02_181_01.pdf (267 KB)
The authors thank Dr. Robert Conley for his helpful reviews of the article, Kristen Ogle and the FID-MC-HGKA study clinical operations team for project management, Fangyi Zhao for statistical support, Prajakti Kothare for assistance with the presentation of the pharmacokinetic analyses, Svetlana Dominguez for editorial assistance, and all of the investigators and patients in the F1D-MC-HGKA study.